01Principles and purposeThe professional or clinical skill and the decisions it supports.
Antithrombotic medicines are prescribed for different reasons. An anticoagulant may prevent embolic stroke in atrial fibrillation or treat a recent venous clot; an antiplatelet may protect a coronary stent. Stopping each drug therefore exposes the patient to a different hazard. Start with the indication rather than the operation’s standard instruction sheet. The timing of a recent thrombosis or coronary intervention can be more important than the medicine name, and may require postponement of an elective procedure or specialist input before interruption is considered.
The operation introduces a competing risk whose severity is not captured by anticipated blood loss alone. A small bleed in a confined space may be devastating, while minor skin bleeding can be controlled directly. Anaesthesia adds further considerations, particularly spinal or epidural procedures and catheter removal. The plan must cover the whole period: last dose, any temporary alternative, operation, postoperative prevention, catheter management and return to usual therapy. A preoperative hold without a restart instruction leaves half of the clinical decision unfinished.
Practical guidance and product information answer related but different questions. The current apixaban SmPC gives licensed treatment regimens and precautions; the UKCPA handbook provides a procedure-based interruption approach. A published timing schedule assumes an appropriate regular dose and relevant patient characteristics. Renal dysfunction, low body weight, interacting medicines, recent thrombosis or uncertain adherence may make the standard example unsuitable. Write the actual dates and doses to omit rather than a phrase such as stop two days before, which different patients and teams may interpret differently.
Key points
- Establish the medicine, indication, dose and exact last administration before choosing an interruption plan.
- Bleeding risk depends on both the procedure and the consequences of bleeding in that anatomical space.
- Use an appropriate renal assessment and identify recent VTE, coronary stents and other high-risk indications.
- Patients taking apixaban generally do not require therapeutic LMWH bridging during a planned interruption.
- Normal routine coagulation tests do not reliably exclude clinically important apixaban activity.
- Restarting needs secure haemostasis, suitable oral absorption and a plan that avoids overlapping anticoagulants.
02Situations and prioritiesThe context, relevant information and actions that matter most.
Stopping antiplatelet treatment soon after coronary intervention can expose the patient to serious arterial thrombosis. Establish the intervention date, clinical indication and intended antiplatelet course, then involve cardiology and the procedural team. Routine cancellation of every antiplatelet prescription is not a safe substitute for that assessment.
Apixaban used for a DVT or pulmonary embolism within the preceding three months warrants specialist planning under UKCPA advice. An elective operation may need to be delayed or its strategy changed. Do not apply an uncomplicated atrial-fibrillation interruption example to this different thrombotic risk.
Identify the exact last dose and current physiology, and obtain senior anaesthetic, surgical and haematology advice. A normal PT or aPTT cannot reassure the team that apixaban has no effect. The urgency of intervention and availability of informative drug testing influence the plan.
A patient restarted on apixaban may still have postoperative LMWH charted. Unless a specialist-defined exception applies, concurrent anticoagulants increase bleeding risk. Reconcile the stop and start orders explicitly and explain the transition to the patient and nursing team.
03Assessment and interpretationHow to gather information, assess the situation and recognise uncertainty.
Consider the information, its meaning and its limitations before deciding what follows.
- 01
Reconcile the actual treatment - Why
- Determine what the patient has taken and what it is intended to prevent.
- Interpretation and limitations
- Use the patient, prescription record and relevant specialist letters. Ask about missed or extra doses and the exact timing of the last administration. The medication list can remain unchanged while the patient has already followed a separate preoperative instruction.
- 02
Estimate renal clearance appropriately - Why
- Assess whether drug exposure may persist longer than expected.
- Interpretation and limitations
- UKCPA advises Cockcroft–Gault creatinine clearance for apixaban assessment rather than relying only on reported eGFR. Review current weight and creatinine and seek advice for marked impairment or uncertain estimates. Rapidly changing kidney function makes a single calculated value less dependable.
- 03
Classify the operation and anaesthetic plan - Why
- Match the interruption strategy to bleeding consequence and neuraxial requirements.
- Interpretation and limitations
- Discuss anticipated haemostasis, possible conversion to a larger operation and any epidural catheter. A procedure called minimally invasive may still have significant bleeding consequences. The anaesthetist must agree the relevant neuraxial timing rather than inherit an ordinary ward schedule.
- 04
Interpret haemostasis tests in context - Why
- Use laboratory information to answer a specific question about bleeding or residual drug effect.
- Interpretation and limitations
- INR helps assess vitamin K antagonist effect but does not quantify apixaban activity. Drug-specific assays may be useful in selected urgent cases where available; obtain expert interpretation. Testing should not delay immediately necessary resuscitation or create false assurance from an insensitive test.
04Worked approachesCases with ordered reasoning, an action and a check of the outcome.
01Worked caseWriting an unambiguous apixaban interruptionA 68-year-old with non-valvular atrial fibrillation takes apixaban 5 mg at 08:00 and 20:00. Weight is 84 kg and creatinine clearance 80 mL/min. There has been no recent VTE. Elective high-bleeding-risk abdominal surgery is planned for Friday morning without neuraxial anaesthesia; the team adopts the UKCPA five-omitted-dose schedule.+
- 1Confirm that the stated regular dose and clinical factors fit the planned pathway. Clarify the procedure’s bleeding risk with the operator and confirm that no epidural or spinal technique has been added. The example does not authorise the same schedule for a different patient with severe renal impairment.
- 2Translate the schedule into clock times. The final dose is Tuesday at 20:00. Omit both Wednesday doses, both Thursday doses and the Friday morning dose: five doses omitted, with roughly sixty hours between the last dose and a Friday 08:00 procedure.
- 3Do not add routine therapeutic-dose LMWH bridging for this apixaban interruption. If postoperative pharmacological VTE prevention is indicated while full anticoagulation remains unsafe, that is a separate prophylactic plan based on haemostasis and surgical risk.
- 4Write a provisional restart review for forty-eight to seventy-two hours after high-risk surgery under the UKCPA approach, with actual administration dependent on secure haemostasis, oral absorption and the postoperative course. A timestamp alone must not force a dose during active bleeding or ileus.
- 5At restart, reconcile the chart so any temporary LMWH is stopped and the correct oral dose resumes without duplication. Ask the patient to repeat which tablets to omit and when the team will confirm restarting; verify the final plan again if the operation is rescheduled.
02Antiplatelet decisionA patient with a coronary stent needs another operationA patient taking dual antiplatelet treatment after coronary intervention is listed for an elective procedure with appreciable bleeding risk.+
- 1Obtain the stent and acute coronary syndrome history and contact the relevant cardiology team. Determine whether delay of the elective operation would reduce thrombotic risk without unacceptable harm from the surgical condition.
- 2Agree which antiplatelet, if any, can be interrupted and whether another should continue. UKCPA gives a seven-day clopidogrel interruption for many non-cardiac procedures when interruption is appropriate, with specialist alternatives for high thrombotic risk; this is not permission to stop recent-stent treatment automatically.
- 3Document the restart plan and the consequences of an unexpected delay. LMWH is not a simple replacement for platelet inhibition at a coronary stent, and any proposed substitute needs an indication-specific specialist rationale.
03Urgent operationResidual anticoagulation cannot be excludedAn adult took apixaban that morning and now needs urgent abdominal surgery.+
- 1Stop further apixaban and establish how urgently the operation must occur. Involve haematology and anaesthesia while the surgical team assesses whether a short delay is clinically acceptable.
- 2Consider appropriate drug-specific testing and haemostatic measures with specialist advice. Do not use a normal routine clotting screen to permit neuraxial intervention, and do not assume a reversal medicine licensed for bleeding is automatically established for preoperative reversal.
- 3Plan postoperative thrombosis prevention and eventual resumption from the outset, while allowing the operation and bleeding course to determine timing. Handover should include the last dose and any reversal or haemostatic treatment actually given.
05Relevant medicines and safetySpecific regimens and precautions when the skill involves prescribing.
Apixaban: established treatment for non-valvular atrial fibrillation
Licensed adult stroke-prevention regimen: 5 mg orally twice daily, continued long term while indicated. For NVAF, use 2.5 mg orally twice daily if at least two apply: age 80 years or over, weight 60 kg or less, serum creatinine 133 micromol/L or more. Severe renal impairment at creatinine clearance 15–29 mL/min also requires the 2.5 mg twice-daily NVAF regimen. Perioperative omission and restart follow the individual written plan.Avoid active clinically significant bleeding and inappropriate concurrent anticoagulants. Review renal function, interacting strong CYP3A4/P-glycoprotein modifiers and oral absorption. It is not recommended at creatinine clearance below 15 mL/min or on dialysis in the UK SmPC. Do not give with an indwelling neuraxial catheter; restarting requires anaesthetic agreement where relevant.
06Feedback, follow-up and evidenceReview outcomes, seek feedback and identify what to improve.
- Confirm the last actual dose on admission and amend the plan if the operation moves. A postponed case can acquire either excessive interruption or an unexpectedly short interval unless someone recalculates the schedule.
- Review haemostasis, renal function, oral intake and further procedural needs before resumption. New vomiting or ileus may make oral absorption unreliable even when the patient can physically swallow a tablet.
- Check each transition for duplicate anticoagulants and specify when temporary prophylaxis stops. The discharge summary should identify the continuing indication, dose and any specialist follow-up.
- Explain signs of significant bleeding and thromboembolism and how to obtain help. Patients should not independently compensate for omitted preoperative doses by doubling the restart dose.
07Special situationsVariants, exceptions and circumstances that change the usual approach.
Vitamin K antagonists differ
Warfarin has a different offset, monitoring and reversal strategy from a DOAC. Its dose is individualised to the indication and INR. Whether bridging is needed depends on thrombotic risk; a protocol designed for a mechanical valve must not be applied to every person with atrial fibrillation.
Antiplatelets are not interchangeable
Aspirin and P2Y12 inhibitors act on platelets, while anticoagulants inhibit coagulation pathways. Their interruption decisions depend on different indications and recovery mechanisms. A generic blood-thinner label hides information required for a safe perioperative plan.
Neuraxial timing is not an afterthought
A schedule suitable for the operation may not meet the anaesthetic team’s requirements for needle placement or catheter removal. Confirm the specific current guidance and patient factors. Neurological symptoms after neuraxial procedures require urgent assessment for a compressive complication.
Reversal is a specialist decision
Available reversal and haemostatic agents have distinct licensed indications, evidence and thrombosis risks. Selection depends on the drug, timing, bleeding severity and urgency. Avoid presenting any agent as a universal antidote that automatically makes an operation safe.
08Common pitfallsFrequent interpretation and management errors.
- 01
Stopping all antithrombotics according to one generic instruction without identifying a recent stent or thrombosis.
- 02
Adding therapeutic LMWH bridging automatically when a patient temporarily stops apixaban for elective surgery.
- 03
Interpreting a normal INR as evidence that a direct factor Xa inhibitor has no remaining anticoagulant effect.
- 04
Restarting oral anticoagulation by the calendar alone while bleeding continues or temporary LMWH remains active.